(Reuters) – Eli Lilly has entered into a research deal with artificial intelligence-focused firm Genetic Leap for up to $409 million to develop genetic medicines, the latter said on Thursday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
Comments